This is a prospective, randomized phase 3 trial. Breast cancer patients with axillary lymph node-positive or supra/subclavicular lymph node metastasis underwent neoadjuvant chemotherapy were included. Patients underwent regional nodal irradiation along with breast or chest wall irradiation and randomly allocated to either IMNI or no IMNI.
Age
18–75
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Histologically confirmed invasive breast cancer
Underwent neoadjuvant chemotherapy
Eastern Cooperative Oncology Group Performance Status Scale 0-2
ypN+ after neoadjuvant chemotherapy or supraclavicular/subclavicular lymph node metastasis before system therapy
No distant metastases
No internal mammary nodes metastases based on images before system therapy
Willing to follow up
Written,informed consent
You may not be if
Without neoadjuvant chemotherapy
Distant metastases
Simultaneous bilateral breast cancer
Pathological confirmation or imaging consideration of lymph node metastasis in the internal mammary before system therapy
Had simultaneous or previous secondary malignancies, except for non-malignant melanoma skin cancer, papillary thyroid / follicular carcinoma, cervical carcinoma in situ, contralateral non-invasive breast cancer
